Company news
Proqr Therapeutics N.v. (NASDAQ:PRQR) news
Proqr Therapeutics N.v. news releases on 6ix. Latest, Sep 23, 2026: ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf…
Press releases & updates
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
September 23, 2026
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
September 9, 2026
ProQR to Participate in Upcoming Investor Conferences in September 2026
September 2, 2026
ProQR Announces Second Quarter 2026 Operating and Financial Results
August 13, 2026
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
June 25, 2026
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
June 25, 2026
ProQR Announces First Quarter 2026 Operating and Financial Results
May 12, 2026
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
May 11, 2026
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
May 4, 2026
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
April 30, 2026
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
April 7, 2026
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
March 25, 2026
ProQR Announces Year End 2025 Operating and Financial Results
March 12, 2026
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
March 3, 2026
ProQR Announces Planned Changes to Board Composition
February 9, 2026
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 8, 2026
ProQR to Participate in 8th Annual Evercore Healthcare Conference
December 1, 2025
ProQR Announces Third Quarter 2025 Operating and Financial Results
November 6, 2025
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
October 19, 2025
ProQR to Participate in Upcoming Investor Conferences in October 2025
October 13, 2025
ProQR Announces Second Quarter 2025 Operating and Financial Results
August 7, 2025
ProQR Announces Upcoming Presentation at RNA Editing Summit
July 28, 2025
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
June 26, 2025
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
May 12, 2025
ProQR Announces First Quarter 2025 Operating and Financial Results
May 8, 2025
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
May 2, 2025
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
May 1, 2025
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
April 14, 2025
ProQR Announces Year End 2024 Operating and Financial Results
March 13, 2025
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
December 10, 2024
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
December 9, 2024
ProQR Announces Third Quarter 2024 Operating and Financial Results
November 6, 2024
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
October 24, 2024
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
October 21, 2024
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 21, 2024
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
September 9, 2024
ProQR Announces Second Quarter 2024 Operating and Financial Results
August 7, 2024
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
June 17, 2024
ProQR Announces First Quarter 2024 Operating and Financial Results
May 8, 2024
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
May 7, 2024
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
April 22, 2024
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
April 21, 2024
ProQR Announces Year End 2023 Operating and Financial Results
March 12, 2024
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
February 14, 2024
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 7, 2023
ProQR Announces Third Quarter 2023 Operating and Financial Results
November 6, 2023
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 5, 2023
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 27, 2023
ProQR Therapeutics Provides Update on Ophthalmic Assets
September 26, 2023
ProQR Announces Second Quarter 2023 Operating and Financial Results
August 2, 2023